AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02083653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym004 (9/6 mg/kg)
Description: Sym004 is a 1:1 mixture of two mAbs (futuximab and modotuximab) which bind to two non-overlapping epitopes of the EGFR.
Study NCT02083653 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Supportive Care (BSC)
Description: BSC is the best palliative care as per Investigator's discretion, excluding antineoplastic agents. BSC may include, but is not limited to, antibiotics, analgesics, antiemetics, blood transfusions, and nutritional support.
Study NCT02083653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil (5-FU)
Description: 5-FU will be administered at doses and schedules as per Investigator's discretion and in line with the local package insert.
Study NCT02083653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine will be administered at doses and schedules as per Investigator's discretion and in line with the local package insert.
Study NCT03304184 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Photac-fil
Description: Application of a tooth colored filling in a non-cavitated dental lesion.
Study NCT03304184 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biodentine
Description: Application of a white colored filling in a non-cavitated dental lesion.
Study NCT05242133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon beta-1a
Description: Pegylated interferon beta-1a (CinnaGen) autoinjector (Physioject™),125 mcg, subcutaneous (SC) injection, every 2 weeks, for 24 months
Study NCT05242133 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon Beta-1A Prefilled Syringe
Description: Interferon Beta-1A Prefilled Syringe, CinnoVex® (CinnaGen), 30 mcg, intramuscular injection, once a week, for 24 months
Study NCT05907187 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cervical Cancer Prevention Education
Description: Participants will receive in-person, one-time health education on the importance of cervical cancer screening using a short intervention/educational script; and motivation to encourage women to have human papillomavirus (HPV) screening. Participants will also be informed of the nature and risks of HPV infection, and the importance of seeing a doctor including having a gynecologic exam.
Study NCT02328157 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vitrectomy with cataract surgery and toric IOL
Study NCT02328157 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vitrectomy with cataract surgery and common IOL
Study NCT00366860 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Soy bread
Study NCT03994406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLM2 topical gel
Description: Active topical gel for forehead dermal application
Study NCT03994406 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo topical gel
Description: Placebo topical gel for forehead dermal application
Study NCT02494401 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Internet-based self-management program
Study NCT02494401 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Scleroderma book
Study NCT03030274 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Occlutech AFR device
Description: Catheter-guided placement of an AFR device following balloon atrial septostomy.
Study NCT02801526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-330 16/5mg - A
Study NCT02801526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan 16mg and Amlodipine 5mg
Study NCT02074319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Treatment as usual or standard treatment for psychosis will be common in all arms
Study NCT02074319 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Treatment as usual or standard treatment for psychosis will be common in all arms
Study NCT01064635 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: letrozole for 2-3 years after Tam
Study NCT01064635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole for 5 years after Tam
Study NCT02179749 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mifepristone 1200 mg daily
Description: Mifepristone, 300 mg tablets, Four tablets daily/am for 1-week duration.
Study NCT02179749 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standardized behavioral therapy
Description: Standardized behavioral therapy 1 time per week for 8 week duration.
Study NCT02179749 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standardized behavioral therapy
Description: Standardized behavioral therapy 1 time per week for 8 week duration.
Study NCT02179749 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets, Four tablets daily/am for 1-week duration.
Study NCT00675870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRX 195183 Soft Gelatin Capsule
Description: Daily oral NRX 195183 administration for 90 days to assess CR rate. Patients with CR may continue maintenance therapy after a 2-week drug holiday. Maintenance therapy will consist of two 3-month daily oral NRX 195183 administration separated by a 2-week drug holiday.
Study NCT02812251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-61393215
Description: JNJ-61393215 (projected dose levels as described above for Part 1) will be administered as an oral suspension.
Study NCT03032640 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral Glucose Tolerance Test (OGTT)
Description: Once we test the fasting plasma glucose (after an overnight fast), subject will receive a 75g glucose beverage they will have to drink within 5 minutes. Then after drinking the beverage, 8 blood samples will be collected through the IV catheter, over the next 3 hours.
Study NCT03032640 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of dietary compliance
Description: Assessment of consumption of non-caloric artificial sweeteners
Study NCT03032640 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stool sampling
Description: Subjects will provide a stool sample.
Study NCT03032640 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Saccharin
Description: Subjects in group 1 and group 3 will be provided with sodium saccharin.
Study NCT03032640 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects in group 2 will be provided with placebo.
Study NCT03032640 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lactisole
Description: Subjects in group 3 and group 4 will be provided with lactisole.
Study NCT01966198 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tilt test
Description: The experiment protocol consists of a sequence of passive postural changes gained with a tilt table, each of them lasting 10 minutes. The sequence consists of: (i) baseline recording in supine position; (ii) tilt at 45 degrees angle; (iii) recovery period in supine position; (iv) tilt at 90 degrees angle and (v) recovery in supine position.
Study NCT02742532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Intranasal oxytocin 40 IU
Study NCT02742532 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intranasal saline solution
Study NCT01335412 — intervention group
Intervention type: BIOLOGICAL
Intervention: Japanese Encephalitis Virus vaccine, inactivated, adsorbed
Description: 2 x 6mcg / 0.5mL intramuscular injection, Day 0 and 28 (Primary series) or 1x 6mcg / 0.5mL intramuscular injection (Booster)
Study NCT00366860 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Soy bread
Study NCT00743587 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral, a double-dummy approach will be used to maintain the blind between active tablet and capsule doses
Study NCT00743587 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Oral, 1 x 20mg controlled-release tablets
Study NCT00743587 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Oral, 2 x 50mg immediate release capsules
Study NCT00743587 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Oral, 1 x 500mg enteric-coated
Study NCT02705040 — intervention group
Intervention type: OTHER
Intervention: Normal
Description: bone mineral density T>=-1.0
Study NCT02705040 — intervention group
Intervention type: OTHER
Intervention: Osteopenia
Description: bone mineral density -1.0>T>=-2.5
Study NCT02705040 — intervention group
Intervention type: OTHER
Intervention: Osteoporosis
Description: bone mineral density T\<-2.5
Study NCT02450773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: 40 mg furosemide on postpartum day 1-6
Study NCT02450773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium chloride
Description: 20 meq potassium chloride on postpartum day 1-6
Study NCT02450773 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo #1
Description: Placebo (for furosemide)
Study NCT02450773 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo #2
Description: Placebo (for KCl)
Study NCT03242603 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-GD2 in combination with NK cells
Description: Haploidentical donor NK cells will be expanded over 10 days and infused in combination with anti-GD2. Anti-GD2 will be given as daily infusion for 5 days ; D-1, 0,+1, +2 and +3. NK cells will be infused at single dose on day 0. The patient will receive cyclophosphamide 60mg/kg on day -3 and day -2 prior to the NK cell infusion. IL- 2 will be given subcutaneously for 6 doses every alternate day starting on day -1, for NK cell survival.
Study NCT01132638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Pantoprazole
Description: 1 capsule daily, 40 mg, orally, 30 minutes before breakfast
Study NCT01132638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Esomeprazole
Description: 1 capsule daily, 40 mg, orally, 30 minutes before breakfast
Study NCT00823550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: entecavir 0.5 mg QD
Study NCT00823550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine
Description: lamivudine 100 mg QD
Study NCT02142920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05212384
Description: Single 89 mg Dose via 30 minute IV infusion
Study NCT01722916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronidase
Study NCT00856934 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Platelet Rich Plasma
Description: Platelet Rich Plasma isolated from patient blood sprayed onto wound bed along with 10% Calcium Chloride solution in a 10 to 1 proportion.
Study NCT00856934 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Keratinocyte suspension
Description: Autologous keratinocytes isolated from skin biopsy suspended in platelet rich plasma before spraying.
Study NCT00856934 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Standard dressings
Description: Three layers of paraffin gauze, topped with standard dry bandages and an elastic bandage.
Study NCT00856934 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard dressings
Description: Three layers of paraffin gauze, topped with standard dry bandages and an elastic bandage.
Study NCT02520999 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auto PC(Acemedical, Goyang-si, Korea) - 0mmHg(control)
Description: Blood pass through infusion set without external pressure.
Study NCT02520999 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auto PC(Acemedical, Goyang-si, Korea) - 150mmHg
Description: Blood pass through infusion set under external pressure (150mmHg)
Study NCT02520999 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auto PC(Acemedical, Goyang-si, Korea) - 200mmHg
Description: Blood pass through infusion set under external pressure (200mmHg)
Study NCT02520999 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auto PC(Acemedical, Goyang-si, Korea) - 250mmHg
Description: Blood pass through infusion set under external pressure (250mmHg)
Study NCT02520999 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auto PC(Acemedical, Goyang-si, Korea) - 300mmHg
Description: Blood pass through infusion set under external pressure (300mmHg)
Study NCT03518658 — intervention group
Intervention type: OTHER
Intervention: Evaluation Group
Description: Patient receiving exposure to the MyCareLink Heart App during device pairing
Study NCT03518658 — intervention group
Intervention type: OTHER
Intervention: Control Group (Historical)
Description: Patients receiving exposure to the CareLink Monitor 2490 (Excluding wireless model 2490C). The patients' data will be extracted from Medtronic de-identified CareLink™ database.
Study NCT03657381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection
Description: Biological: F520 single-dose:0.2mg/kg, 1.0mg/kg, 3.0mg/kg, 200mg/times, 10mg/kg; multiple dosing: 1mg/kg, 3mg/kg, 200mg/times, 10mg/kg, treat every 2 weeks; multiple dosing: 3mg/kg, 200mg/times, treat every 3 weeks.
Study NCT04203927 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 25 MG
Description: SGLT-2 inhibitor
Study NCT04842994 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IONM tube
Description: The standardized technique of IONM-RLNs (bilaterally) will be used, including indirect vagal response evaluation at the beginning and also at the end of surgery according to the recommendations formulated by the International Intraoperative Neural Monitoring Study Group (INMSG) (Randolph GW, Dralle H. 2011).
Study NCT02812251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered.
Study NCT04267159 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acute cardioversion
Description: Acute restoration of sinus rhythm by medical or electrical cardioversion in the emergency department
Study NCT04267159 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Delayed cardioversion
Description: Delayed restoration of sinus rhythm by medical or electrical cardioversion in the out-patient clinic
Study NCT02638051 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modulated Electro-Hyperthermia (mEHT)
Description: MEHT is a descendant of hyperthermia initially based on nano-thermal but not temperature-dependent effects of electromagnetic fields and special fractal modulation, whose effect could 3-4 times exceed the effect of the overall heating (macroscopic temperature elevation). MEHT does not require hyperthermia-range temperatures and could be performed safely without invasive thermal control. EHY-2000 local machine is used for mEHT in the trial.
Study NCT02638051 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TCM Herbal Decoction (Shi Pi)
Description: Shi Pi Decoction can warm Yang, invigorate the spleen, promote Qi circulation to induce diuresis and treat Foot-Taiyin meridian in Gu Zhang.
Study NCT02638051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IPCI (CDDP+5FU)
Description: Intraperitoneal chemoinfusion of CDDP (30-60 mg) and 5-fluorouracil (500-600 mg/sqm).
Study NCT01454414 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Permethrin Impregnated Uniforms
Description: Uniforms treated with permethrin according to proprietary process used by Insect Shield, Inc.
Study NCT00033306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone
Study NCT00033306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoropyrimidine
Study NCT00033306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Study NCT03277716 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE: With the patient under local anesthesia, a 5F French catheter was introduced into the abdominal aorta via the femoral artery using the Seldinger technique. Hepatic arterial angiography was performed using fluoroscopy to guide the catheter into the celiac and superior mesenteric arteries. Then, the feeding arteries, tumor, and vascular anatomy surrounding the tumor were identified. Subsequently, a microcatheter was super-selectively inserted into the feeding arteries. Then, a mixture solution containing chemotherapeutic agents and embolic agents were infused into the artery according to the size and blood supply of the tumors.
Study NCT03277716 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MWA
Description: MWA: All patients were instructed to fast from all foods for 12 hours preoperatively. During the procedure, a CT scan was used to locate the liver tumors, and to design the optimal puncture needle route. Routine disinfection and local anesthesia was applied around the puncture point, and a 16-gauge microwave antenna was gradually inserted into the tumor along the pre-determined angle. Settings of the MWA parameters depended on the manufacturer's recommendation and our experience.
Study NCT03277716 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MWA system
Description: MWA system is a kind of medical treatment instrument to restrain and kill tumor based on microwave heating technique and biology heating effect theory.
Study NCT03277716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemoembolization
Description: Chemotherapeutic drugs: adriamycin，epirubicin and pirarubicin. Embolic agent: lipiodol and embolic microspherea The mixture solution containing chemotherapeutic drugs and embolic agent were infused into the artery according to by the number and size of the lesions, liver and kidney function of the patient, and blood supply of the tumors.
Study NCT04451668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT218
Description: once nightly sodium oxybate extended release
Study NCT03157726 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transurethral plasmakinetic enucleation of prostate
Description: Transurethral plasmakinetic enucleation of prostate(PAKEP),an operation mode devised by Liu Chunxiao Team in southern medical university urology department. The theory of the operation is using transurethral resectoscope instead of the finger in the open operation, to find the surgical capsule of prostate and to peel the hyperplastic prostate gland visually in a antidromic way.
Study NCT03157726 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transurethral resection of prostate
Description: Transurethral resection of prostate(TURP), a kind of mature minimally invasive surgery of prostate , taking the place of the traditional open surgery in 1930s , still is the gold standard operation for surgical treatment of BPH.
Study NCT04108663 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Effect of tDCS on cognitive control task performance
Description: Added verum or sham tDCS while working on a cognitive control task.
Study NCT04108663 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Effect of tDCS on cognitive control task performance
Description: Added verum or sham tDCS while working on a cognitive control task.
Study NCT00750919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esmirtazapine
Study NCT02527915 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental Health eConsults
Description: Providers in primary care clinics who receive the intervention will be able to use electronic consultations (eConsults) with psychiatrists. If a primary care provider wishes to use eConsults, he/she will enter a specific question about a patient in the electronic medical record system and submit as an eConsult. A psychiatrist will review the question and the patient's record, and send a response back to the primary care provider within one business day.
Study NCT02527915 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Care as usual
Description: Providers in primary care clinics will deliver care as usual to their patients.
Study NCT03139864 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: controlled physical activity
Description: Comparison between infants with type 1 diabetes and infants without type 1 diabetes during exercise :
Study NCT03139864 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: controlled physical activity
Description: Comparison between infants with type 1 diabetes and infants without type 1 diabetes during exercise :
Study NCT04650334 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Collaborative Care
Description: Health services intervention to implement a team based model of care for perinatal depression.
Study NCT03350204 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Meniscectomy
Description: This will be to see what occurs in both kinetics and kinematics after you have a surgery and how this links on to osteoarthritis
Study NCT03350204 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Helathy control comparison
Description: This group will be used to get a baseline for normal and natural walking, running and other several tasks which will be used as a comparison for the meniscus injury group.